Immunovant Inc (IMVT)

Currency in USD
33.21
-0.07(-0.21%)
Closed·
33.68+0.47(+1.42%)
·
IMVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
32.4533.82
52 wk Range
21.8645.42
Key Statistics
Prev. Close
33.21
Open
33.17
Day's Range
32.45-33.82
52 wk Range
21.86-45.42
Volume
926.73K
Average Volume (3m)
1.43M
1-Year Change
40.1857%
Book Value / Share
3.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMVT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
48.63
Upside
+46.42%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Immunovant Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Analyst Ratings

13 Buy
4 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 48.63
(+46.42% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Truist Securities
Hold33.00-0.63%30.00MaintainNov 10, 2026
Wells Fargo
Buy47.00+41.52%45.00MaintainNov 10, 2026
H.C. Wainwright
Buy41.00+23.46%-MaintainSep 24, 2026
Cantor Fitzgerald
Buy---MaintainAug 25, 2026
Stifel
Buy57.00+71.64%49.00MaintainAug 06, 2026

Immunovant Inc SWOT Analysis


Pioneering Treatment
Immunovant's novel anti-FcRn therapy shows promise for autoimmune diseases, particularly Graves' disease, with potential for best-in-class efficacy
Market Potential
Explore the substantial opportunity in Graves' disease, with an estimated 20,000 high-need patients diagnosed annually in the US
Analyst Optimism
Price targets range from $36 to $58, suggesting significant upside potential despite recent stock decline. Average target stands at $57
Strategic Expansion
Delve into Immunovant's ambitious plan to target 10 indications by 2026, diversifying risk and expanding market potential
Read full SWOT analysis

Immunovant Inc Earnings Call Summary for Q2/2027

  • Roivant posted Q2 adjusted EPS of -$0.47, beating consensus of -$0.74 by 36.5%; shares surged 11.82% premarket to $34.14.
  • LISRAYA generated $31M in net revenue during first five weeks post-launch; hundreds of patients on paid drug by quarter-end.
  • Company holds $4.2B cash as of Sept. 30; repurchased $280M in stock over six months, reflecting strong liquidity position.
  • Management eyes busy 2027 with brepocimab filing for uveitis, IMVT-1402 data in Graves' disease, and mosliciguat expansion plans.
  • Regulatory path for IMVT-1402 in rheumatoid arthritis still under FDA discussion; Sjögren's syndrome development discontinued.
Last Updated: 2026-11-09, 08:56 a/m
Read Full Transcript

Earnings

Latest Release
Nov 09, 2026
EPS / Forecast
-0.47 / -0.74
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMVT Income Statement

Compare IMVT to Peers and Sector

Metrics to compare
IMVT
Peers
Sector
Relationship
P/E Ratio
−13.5x−1.6x−0.2x
PEG Ratio
−1.41−0.030.00
Price/Book
10.5x2.3x2.6x
Price / LTM Sales
-7.9x2.7x
Upside (Analyst Target)
46.4%175.2%68.5%
Fair Value Upside
Unlock8.6%11.5%Unlock

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
45.11M21.80%1.50B
Other Institutional Investors
191.52M78.20%6.37B
Public Companies & Retail Investors
0.000.00%0.00
Total
236.63M100.00%7.88B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Roivant Sciences Ltd.54.76%113,317,0073,771,190
FMR LLC7.58%15,692,527522,247

People Also Watch

96.80
KOD
-3.90%
95.11
KNSA
+0.93%
16.47
RLAY
-4.63%
91.95
MIRM
+0.40%
45.45
ALKS
-2.32%

FAQ

What Is the Immunovant (IMVT) Stock Price Today?

The Immunovant stock price today is 33.21 USD.

What Stock Exchange Does Immunovant Trade On?

Immunovant is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immunovant?

The stock symbol for Immunovant is "IMVT."

What Is the Immunovant Market Cap?

As of today, Immunovant market cap is 6.87B USD.

What Is Immunovant's Earnings Per Share (TTM)?

The Immunovant EPS (TTM) is -2.55.

When Is the Next Immunovant Earnings Date?

Immunovant will release its next earnings report on Feb 16, 2027.

From a Technical Analysis Perspective, Is IMVT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Immunovant Stock Split?

Immunovant has split 0 times.

How Many Employees Does Immunovant Have?

Immunovant has 315 employees.

What is the current trading status of Immunovant (IMVT)?

As of Nov 18, 2026, Immunovant (IMVT) is trading at a price of 33.21 USD, with a previous close of 33.21 USD. The stock has fluctuated within a day range of 32.45 USD to 33.82 USD, while its 52-week range spans from 21.86 USD to 45.42 USD.

What Is Immunovant (IMVT) Price Target According to Analysts?

The average 12-month price target for Immunovant is 48.63 USD, with a high estimate of 62 USD and a low estimate of 33 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +46.42% Upside potential.

What Is the IMVT Premarket Price?

IMVT's last pre-market stock price is 33.68 USD. The pre-market share volume is 8,600.00, and the stock has decreased by 0.47, or 1.42%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.